RxDoctor Payments Data

Jae Pak, MD

Geriatric Psychiatry · Snellville, GANPI 1740280551

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $534, 2.2 times the $239 reported in 2019.

$1,873in general payments, 2019–2025

Across 103 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$384
  • Teva Pharmaceuticals USA, Inc.$237
  • Avanir Pharmaceuticals, Inc.$182
  • Neurocrine Biosciences, Inc.$161
  • AbbVie$152
  • Alkermes, Inc.$132
  • plus $625 from 10 others

What the payments were for

  • Food & beverage$1,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few geriatric psychiatry providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$333,365
Medicare patients
413
Services billed
3,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$46,675
EliquisApixaban52$26,551
RexultiBrexpiprazole13$21,871
Memantine Hcl420$12,159
Quetiapine Fumarate880$10,168
BelsomraSuvorexant21$9,058
Chlorpromazine Hcl46$8,080
Rivastigmine40$7,186
Venlafaxine Hcl ErVenlafaxine Hcl374$6,247
Aripiprazole119$5,652
Clonazepam601$4,147
Donepezil Hcl628$4,004
Olanzapine210$3,997
JardianceEmpagliflozin11$3,693
Bupropion XlBupropion Hcl214$3,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$116$46,67516 claims
Otsuka America Pharmaceutical, Inc.Rexulti$384$21,87113 claims
Lilly USA, LLCOlanzapine$19$3,997210 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other geriatric psychiatry in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →